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Atherosclerosis, the main underlying cause of cardiovas-cular disease, is traditionally considered a lipid-driven 
disease. However, numerous studies have shown that ather-
osclerosis is influenced by the innate and adaptive immune 
system with cytokines involved in all stages of atherogen-
esis.1,2 Moreover, the CANTOS-trial (Canakinumab Anti-
inflammatory Thrombosis Outcomes Study) demonstrated 
that an antibody against IL (interleukin)-1β reduced recur-
rent cardiovascular events in patients with a previous my-
ocardial infarction, indicating that inflammation enhances 
cardiovascular risk in humans.3
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Rationale: Several studies have suggested a role for the gut microbiota in inflammation and atherogenesis. A causal 
relation relationship between gut microbiota, inflammation, and atherosclerosis has not been explored previously.
Objective: Here, we investigated whether a proinflammatory microbiota from Caspase1−/− (Casp1−/−) mice accelerates 
atherogenesis in Ldlr−/− mice.
Method and Results: We treated female Ldlr−/− mice with antibiotics and subsequently transplanted them with fecal 
microbiota from Casp1−/− mice based on a cohousing approach. Autologous transplantation of fecal microbiota of 
Ldlr−/− mice served as control. Mice were cohoused for 8 or 13 weeks and fed chow or high-fat cholesterol–rich diet. 
Fecal samples were collected, and factors related to inflammation, metabolism, intestinal health, and atherosclerotic 
phenotypes were measured. Unweighted Unifrac distances of 16S rDNA (ribosomal DNA) sequences confirmed 
the introduction of the Casp1−/− and Ldlr−/− microbiota into Ldlr−/− mice (referred to as Ldlr−/−(Casp1−/−) or Ldlr−/−(
Ldlr−/−) mice). Analysis of atherosclerotic lesion size in the aortic root demonstrated a significant 29% increase in 
plaque size in 13-week high-fat cholesterol–fed Ldlr−/−(Casp1−/−) mice compared with Ldlr−/−(Ldlr−/−) mice. We found 
increased numbers of circulating monocytes and neutrophils and elevated proinflammatory cytokine levels in plasma 
in high-fat cholesterol–fed Ldlr−/−(Casp1−/−) compared with Ldlr−/−(Ldlr−/−) mice. Neutrophil accumulation in the 
aortic root of Ldlr−/−(Casp1−/−) mice was enhanced compared with Ldlr−/−(Ldlr−/−) mice. 16S-rDNA-encoding sequence 
analysis in feces identified a significant reduction in the short-chain fatty acid–producing taxonomies Akkermansia, 
Christensenellaceae, Clostridium, and Odoribacter in Ldlr−/−(Casp1−/−) mice. Consistent with these findings, cumulative 
concentrations of the anti-inflammatory short-chain fatty acids propionate, acetate and butyrate in the cecum were 
significantly reduced in 13-week high-fat cholesterol–fed Ldlr−/−(Casp1−/−) compared with Ldlr−/−(Ldlr−/−) mice.
Conclusions: Introduction of the proinflammatory Casp1−/− microbiota into Ldlr−/− mice enhances systemic 
inflammation and accelerates atherogenesis.  (Circ Res. 2019;124:94-100. DOI: 10.1161/CIRCRESAHA.118.313234.)
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Gut microbiota is known to be involved in the shaping of the 
immune system during early life. Recent studies have suggested 
a role for the gut microbiota in the regulation of inflammation by 
influencing differentiation of inflammatory cell types, cytokine 
production and hematopoiesis .4–6 A leaky gut and alterations in 
gut microbiota composition can both lead to leakage of endotox-
ins into the circulation that promotes systemic inflammation and 
to the development of obesity and related metabolic diseases.7,8 
Symptomatic atherosclerosis is associated with an altered gut 
metagenome in the human population,9,10 and bacterial DNA 
has been detected in atherosclerotic plaques.11 Furthermore, a 
high blood concentration of the microbiota-dependent metab-
olite trimethyl-amine-N-oxide (TMAO) has been linked to an 
increased risk of atherosclerosis,12–14 indicating a pivotal role 
for the gut microbiota in atherogenesis. In addition, germ-free 
ApoE-deficient (ApoE−/−) mice showed lower circulating lip-
opolysaccharide levels, reduced systemic inflammation, and 
decreased atherogenesis compared with conventionally raised 
ApoE−/− mice.15 Taken together, these findings suggest a triangu-
lar relationship between the gut microbiota, host immunity, and 
atherogenesis; however, proof to support a proinflammatory role 
for the gut microbiota in atherogenesis is lacking.
To examine whether introduction of a proinflammatory 
gut microbiota accelerates atherogenesis, we exposed fe-
male Ldlr−/− mice to the proinflammatory gut microbiota of 
Casp1−/− mice,7 as previous reports have demonstrated that 
alterations in their microbiota sensitize mice to the develop-
ment of several inflammatory diseases.7,16 The gut microbi-
ota of Casp1−/− mice promoted atherosclerosis and increased 
blood leukocyte numbers, proinflammatory plasma cy-
tokines, and neutrophil accumulation in atherosclerotic 
plaques, whereas plasma lipid and TMAO levels, and gut 
integrity were unaffected. The Casp1−/− microbiota reduced 
microbiota-derived anti-inflammatory short-chain fatty acids 
(SCFAs).
Methods
The authors declare that all data supporting the findings of this study 
are available in its Online Data Supplement.
Results
Casp1−/− Microbiota Successfully Introduced into 
Ldlr−/− Mice
To study whether a proinflammatory microbiota accelerates 
atherogenesis, we exposed antibiotic-treated Ldlr−/− mice to 
the gut microbiota of Casp1−/− mice through fecal microbi-
ota transplantation via a cohousing approach7 (Figure 1A). 
Autologous transplantation of fecal microbiota from Ldlr−/− 
mice into antibiotic-treated Ldlr−/− mice via a cohousing 
approach7 served as control. Analysis of fecal microbiota 
composition at time of sacrifice revealed both cohousing and 
diet-associated changes in gut microbial ecology (Figure 1B). 
Unweighted UniFrac distances of 16S-rDNA (ribosomal 
DNA) sequences, a measure for β-diversity, demonstrated clus-
tering between the Ldlr−/− mice receiving Casp1−/− microbiota 
Nonstandard Abbreviations and Acronyms
HFC high-fat cholesterol-rich
IL interleukin
NF-κB nuclear factor κB
TMAO trimethylamine-N-oxide





• Atherosclerosis, the main underlying cause of cardiovascular disease, 
is influenced by both—the innate and adaptive immune systems.
• Gut microbiota shape the immune system during early life and play a 
role in regulating inflammation by influencing the differentiation of in-
flammatory cell types, the production of cytokines, and hematopoiesis.
• Inflammation and atherosclerosis are linked to changes in gut micro-
biota composition; however, there is little evidence to support a proin-
flammatory role of gut microbiota in atherosclerosis.
What New Information Does This Article Contribute?
• The presence of a proinflammatory microbiota derived from 
Caspase1−/− (Casp1−/−) mice is sufficient to promote inflammation and 
atherosclerosis in antibiotic-treated Ldlr−/− mice, a mouse model with 
a human-like lipoprotein profile.
• The gut microbiota of Casp1−/− mice increases inflammation in antibi-
otic-treated Ldlr−/− mice, reflected by increased blood leukocyte num-
bers, particularly monocytes and neutrophils, proinflammatory plasma 
cytokines, and neutrophil accumulation in atherosclerotic plaques.
• The gut microbiota of Casp1−/− mice reduces the microbiota-de-
rived anti-inflammatory short-chain  fatty acids in antibiotic-treated 
Ldlr−/− mice, whereas plasma lipid, trimethylamine-N-oxide levels, and 
gut integrity are unaffected.
Several human studies have provided evidence that links the gut 
microbiota to cardiovascular disease. Nevertheless, the evidence 
supporting a causal role of the gut microbiota in cardiovascular 
disease is limited to the understanding of the importance of tri-
methylamine-N-oxide in atherogenesis. Recent findings suggest 
a pivotal role of the gut microbiota in regulating inflammation. 
Here, we provide a novel, alternative mechanism by which the 
gut microbiota may contribute to atherogenesis, independent of 
plasma lipids and trimethylamine-N-oxide levels. We show that 
introduction of a proinflammatory gut microbiota into a mouse 
model with a human-like lipoprotein profile increases systemic 
inflammation and accelerates atherogenesis. This was associ-
ated with a reduction in microbiota-derived anti-inflammatory 
short-chain  fatty acids, implying a causal relationship between 
microbiota composition, inflammation, and atherosclerosis. 
Collectively, these findings indicate that manipulation of the gut 
microbiota composition may be potentially effective treatment 
strategy to protect against inflammation and atherosclerosis and 
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(referred to as Ldlr−/−[Casp1−/−] mice) and the Casp1−/− donor 
mice (Figure 1B; Online Table II). Analogously, we observed 
clustering between Ldlr−/− mice receiving the autologous mi-
crobiota transplantation (referred to as Ldlr−/−(Ldlr−/−) mice) 
and their respective donor mice. We also observed a clear sep-
aration between mice fed chow or high-fat cholesterol (HFC) 
diet (Figure 1B; Online Table II), and this was consistent for 
all donor and recipient mice. As expected, α-diversity was not 
different between Ldlr−/−(Ldlr−/−) and Ldlr−/−(Casp1−/−) mice 
(Online Figure IB). Altogether, these data demonstrate that 
Casp1−/− and Ldlr−/− microbiota were successfully transferred 
into Ldlr−/− mice.
Casp1−/− Dysbiosis Promotes Atherosclerosis in 
Ldlr−/− Mice Fed an HFC Diet
We analyzed atherosclerotic lesion size in the aortic root, 
and we found that Casp1−/− microbiota did not affect ath-
erosclerotic lesion size in Ldlr−/− mice fed chow or an HFC 
diet for 8 weeks (Figure 2A and 2B). However, atheroscle-
rotic lesion size was increased by 29% in Ldlr−/−(Casp1−/−) 
mice compared with Ldlr−/−(Ldlr−/−) mice after 13 weeks of 
HFC feeding (Figure 2A and 2B; P<0.05). The collagen and 
macrophage content in aortic root sections was not different 
between the mice (Online Figure IIA), indicating that lesion 
size but not severity was increased. In the aortic arches, gene 
Figure 1. Transplantation of Casp1−/− microbiota into Ldlr−/− mice via a cohousing approach. Female Ldlr−/− mice aged 12 wk were exposed to fecal 
microbiota derived from Casp1−/− or Ldlr−/− mice for 8 or 13 wk while fed a chow diet or high-fat cholesterol (HFC) diet. A, Experimental setup of the 
cohousing approach. Female Ldlr−/− mice were orally gavaged with a cocktail of broad-spectrum antibiotics for a period of 10 d to suppress intestinal 
microbes. This was followed by daily transfer of used bedding material from cages housing nonantibiotic-treated Ldlr−/− (donor) or Casp1−/− (donor) mice to 
cages housing the antibiotic-treated Ldlr−/− mice for 1 wk. During this period the mice were kept on chow diet or switched to an HFC diet for the remainder of 
the study. The antibiotic-treated Ldlr−/− mice were then cohoused with nonantibiotic-treated Casp1−/− mice (referred to as Ldlr−/−(Casp1−/−) mice) or Ldlr−/− mice 
(autologous transplantation, referred to as Ldlr−/−(Ldlr−/−) mice) in a 3:2 ratio for a period of 8 or 13 wk. B, Principal coordinate analysis plot of Unweighted 
UniFrac distance on the basis of 16S-rDNA (ribosomal DNA)-encoding sequences in feces collected from chow- and HFC-fed Ldlr−/− mice exposed to 
Casp1−/− or Ldlr−/− microbiota for 13 wk. Chow: Ldlr−/− mice (donor), n=8; Ldlr−/−(Ldlr−/−) mice, n=15; Casp1−/− mice (donor), n=9; Ldlr−/−(Casp1−/−) mice, n=14. 
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expression of several macrophage-related and inflammatory 
markers was similar between HFC-fed mice with the excep-
tion of a significant increase in Il-10 expression in Ldlr−/−(C
asp1−/−) mice (Online Figure IIB). Body weight, plasma tri-
glyceride, and cholesterol levels (Online Figure IIIA–IIID) 
also did not differ, and no alteration was observed in plasma 
levels of TMAO, its TMA precursors (choline, l-carnitine, be-
taine, and γ-butyrobetaine; Online Figure IIIE), and TMAO-
producing taxonomies (Online Figure IIIF). Altogether, these 
results exclude plasma lipid levels and TMAO as factors that 
contribute to the increased atherosclerotic lesions in Ldlr−/−(C
asp1−/−) mice.
Casp1−/− Dysbiosis Promotes Inflammation
Next, we assessed whether Casp1−/− dysbiosis accelerates 
atherosclerosis by increasing plasma inflammatory cyto-
kines. We found a significant elevation in the plasma levels 
of IL-1β, IL-2, IL-10, and IFN (interferon)-γ in Ldlr−/−(Ca
sp1−/−) mice after 13 weeks of HFC diet (Figure 3A), whereas 
CXCL1 (chemokine [C-X-C motif] ligand 1), TNF (tumor 
necrosis factor)-α, IL-5 and IL-6 were not affected (Online 
Figure IVB). Flow cytometry analysis showed an increase 
in the number of blood Ly6Clo and Ly6Chi monocytes and 
neutrophils in Ldlr−/−(Casp1−/−) mice compared with Ldlr−/
−(Ldlr−/−) mice accompanied by an increase in white blood 
cell count (Figure 3B; Online Figure IVA), with leukocyte 
percentages being unchanged (Online Figure IVC). We also 
observed increased neutrophil accumulation in atheroscle-
rotic plaques of Ldlr−/−(Casp1−/−) mice compared with Ldlr−/
−(Ldlr−/−) fed an HFC diet for 13 weeks (Figure 3C and 3D). 
These data suggest that Casp1−/− dysbiosis enhances IL-1β 
plasma levels resulting in monocytosis and neutrophilia and 
increased neutrophil accumulation in atherosclerotic plaques.
Exposure to Casp1−/− Microbiota Does Not Impair 
Intestinal Barrier Function in Ldlr−/− Mice Fed an 
HFC Diet
A disturbance in microbiota composition may affect intestinal 
integrity and subsequently promote systemic inflammation7,8 
To investigate the effect of Casp1−/− microbiota on intesti-
nal barrier function, we analyzed the gut microbiota compo-
sition using the linear discriminant analysis (LDA) effect size 
(LEfSe) method. We identified 34 microbial taxonomies that 
differed in abundance between Ldlr−/−(Ldlr−/−) and Ldlr−/−(Ca
sp1−/−) mice (Online Figure VA). Casp1−/− dysbiosis resulted in 
a significant expansion of the genera Bilophila, Streptococcus, 
and Mucispirillum (Online Figure VB–VD) under both chow- 
and HFC-diet conditions. Although these genera are associated 
with intestinal inflammation, and are known to expand under 
inflammatory conditions,17 we did not observe any differences 
in intestinal barrier function, for example, inflammation and 
epithelial injury (Online Figure VIA–VIC). In addition, mucus 
Figure 2. Casp1−/− microbiota promotes atherosclerosis development in Ldlr−/− mice fed high-fat cholesterol (HFC) diet. A, Representative toluidine blue 
stained slides of the aortic root. Scale bars, 400 μm. B, Quantification of atherosclerotic root lesion area. Chow (13 wk): Ldlr−/−(Ldlr−/−) mice, n=15; Ldlr−/−(Casp1−/−)  
mice, n=16. HFC (8 wk): Ldlr−/−(Ldlr−/−) mice, n=19; Ldlr−/−(Casp1−/−) mice, n=19. HFC (13 wk): Ldlr−/−(Ldlr−/−) mice, n=14; Ldlr−/−(Casp1−/−) mice, n=13. In bar 
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layer thickness of the colon (Online Figure VID and VIE) and 
Muc-2 expression (Online Figure VIF) in the colon were not al-
tered between groups, suggesting that the integrity of the mucus 
layer of the colon was not different between Ldlr−/−(Ldlr−/−) and 
Ldlr−/−(Casp1−/−) mice. Although intestinal permeability was 
significantly impaired by HFC feeding, only Ldlr−/−(Casp1−/−) 
mice fed chow diet displayed increased permeability compared 
with Ldlr−/−(Ldlr−/−) mice (Online Figure VIG). These results 
indicate that Casp1−/− microbiota does not change the intesti-
nal barrier function under HFC-diet conditions and, therefore, 
cannot explain the increase in plasma inflammatory cytokines.
Exposure to Casp1−/− Microbiota Lowers SCFA-
Producing Microbial Taxonomies and Cecum 
Concentration of SCFAs
We observed a significant reduction in the abundance of the 
SCFA-producing taxonomies Akkermansia (Figure 4A), 
Christensenellaceae (Figure 4B), Clostridium (Figure 4C), 
and Odoribacter (Figure 4D) in Ldlr−/−(Casp1−/−) mice. As 
previous studies have shown that SCFAs reduce inflamma-
tion,18,19 we measured the concentrations of acetate, propio-
nate, and butyrate in the cecum of the mice. Consistent with 
the lower abundance of SCFA-producing taxonomies, a sig-
nificant reduction was observed in the cumulative levels of 
these SCFAs in Ldlr−/−(Casp1−/−) mice compared with Ldlr−
/−(Ldlr−/−) mice (Figure 4E) and this was mainly because of 
lower acetate levels in the Ldlr−/−(Casp1−/−) mice. Thus, it is 
conceivable that a reduction in the anti-inflammatory SCFAs 
may have contributed to the increased levels of inflammatory 
plasma cytokines of mice exposed to Casp1−/− microbiota.
Discussion
We examined whether a proinflammatory microbiota accel-
erates atherogenesis in female Ldlr−/− mice, a mouse model 
exhibiting dyslipidemia, inflammation, and atherosclerosis, 
when fed a western style diet.20 We found that Casp1−/− micro-
biota increased atherosclerosis in the aortic root in HFC-fed 
Ldlr−/− mice (Figure 1A and 1B). This was accompanied by 
increased proinflammatory plasma cytokines (Figure 3A), in-
creased blood leukocyte numbers, particularly monocytes and 
neutrophils (Figure 3B), increased neutrophil accumulation in 
atherosclerotic plaques (Figure 3C and 3D), and reduced lev-
els of SCFAs in the cecum (Figure 4E). These results imply a 
causal relationship between microbiota composition, inflam-
mation, and atherosclerosis.
We found that in particular the plasma levels of IFN-γ, 
IL-2, and IL-1β were increased in Ldlr−/− mice with Casp1−/− 
dysbiosis, suggesting that accelerated atherosclerosis in these 
mice is partially driven by these cytokines, which is supported 
by previous studies.21–23 Furthermore, we showed an increase 
in peripheral blood leukocytes, which have previously been 
linked to cardiovascular disease.24 Within the leukocyte pop-
ulation, neutrophils and monocytes are important contribu-
tors to atherogenesis.25 Increased monocytes and neutrophils 
in the circulation may lead to infiltration of monocytes and 
neutrophils into atherosclerotic plaques and further promoting 
plaque growth.25
We observed that exposure to Casp1−/− microbiota lowers 
SCFA-producing taxonomies and cumulative cecum concentra-
tions of SCFAs. SCFAs have anti-inflammatory properties and 
Figure 3. Casp1−/− dysbiosis leads to systemic inflammation. A, Plasma cytokines at time of sacrifice. n=10 per group. B, White blood cell (WBC) count and 
immune subsets during week 5 of cohousing. Ldlr−/−(Ldlr−/−) mice, n=18; Ldlr−/−(Casp1−/−) mice, n=17. C–D, Female Ldlr−/− mice aged 12 wk were exposed to fecal 
microbiota derived from Casp1−/− or Ldlr−/− mice for 13 wk while fed high-fat cholesterol (HFC) diet. C, Representative Ly6G-stained slides of the aortic root. Scale 
bars, 100 μm. D, Number of infiltrated neutrophils per 100.000 µm2 characterized by Ly6G-stained slides of the aortic root. Ldlr−/−(Ldlr−/−) mice, n=13; Ldlr−/−(Ca
sp1−/−) mice, n=12. Data represent mean±SEM. *P<0.05 as determined by unpaired 1-tailed Student t test. IFN indicates interferon; and IL, interleukin.D
ow
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can suppress NF-κB (nuclear factor κB) activity in immune 
cells,18 resulting in reduced production of proinflammatory cyto-
kines including IFN-γ, IL-1β, and IL-2.26 Furthermore, SCFAs 
may act as modulators of immune homeostasis by acting as 
HDAC (histone deacetylase) inhibitors.19 Oral butyrate supple-
mentation has recently been shown to attenuate the adhesion and 
migration of macrophages and to decrease proinflammatory cy-
tokines in atherosclerotic plaques.27 Thus, it is tempting to spec-
ulate that the reduction in SCFAs in Ldlr−/− mice after exposure 
to Casp1−/− microbiota may have contributed to increased levels 
of proinflammatory cytokines and leukocytes in the circulation 
and neutrophil accumulation in the atherosclerotic plaque.
It is well recognized that microbial transplantation can 
be transient.13 Thus, we cannot exclude that certain effects on 
TMAO, although not present at time of sacrifice, may have 
been lost throughout the length of the study. In line with this, 
the possibility exists that the inflammatory effects may have 
been dampened over time. Future studies, therefore, should 
include more frequent and earlier time points to rule out these 
possibilities.
Whereas previous studies have shown a decreased abun-
dance of Akkermansia muciniphila on high-fat diet feeding, 
our data show on opposing effect on A muciniphila after HFC 
feeding. A similar effect on high-fat and high-carbohydrate 
diet feeding in mice was recently shown28 and warrants fur-
ther investigation. Nevertheless, promising results have been 
obtained with the administration of A muciniphila resulting in 
protection against atherogenesis in ApoE−/− mice by strength-
ening the gut barrier and preventing metabolic endotoxemia-
induced inflammation.29 Likewise, metformin’s reported 
beneficial effects on atherosclerosis in humans with type I and 
II diabetes mellitus and nondiabetic dysglycaemia may be re-
lated to its ability to enhance the growth of A muciniphila and 
promote SCFA production.30 Together with our findings, this 
indicates that manipulation of the gut microbiota composition 
is an interesting treatment strategy to protect against inflamma-
tion and atherosclerosis and reduce cardiovascular disease risk.
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